Report

reporttype1Version of Safety Report ID1receivedateformat102transmissiondateformat102fulfillexpeditecriteria1Safety Report ID10060391serious1Date Last Updated04/04/2014receiptdateformat102companynumbUS-ACTAVIS-2014-06267occurcountryUSseriousnessother1duplicate1Date Received04/04/2014transmissiondate12/12/2014primarysourcecountryUS

Primary Source

reportercountryUSqualification5

Patient

Weight100SexFemale

Contents

Reaction
- 1)
- 2)
- 3)
- 4)
- 5)
- 6)
- 7)
Drug

Reaction

1)

reactionmeddraversionpt17.0ReactionDrug withdrawal syndromeOutcomeRecovered/resolved

2)

reactionmeddraversionpt17.0ReactionHallucinations, mixedOutcomeRecovered/resolved

3)

reactionmeddraversionpt17.0ReactionPanic attackOutcomeRecovered/resolved

4)

reactionmeddraversionpt17.0ReactionAngerOutcomeRecovered/resolved

5)

reactionmeddraversionpt17.0ReactionLethargyOutcomeUnknown

6)

reactionmeddraversionpt17.0ReactionSomnolenceOutcomeUnknown

7)

reactionmeddraversionpt17.0ReactionDrug interactionOutcomeUnknown

Drug

1)

drugcharacterization1medicinalproductCLONAZEPAM (AELLC)drugbatchnumbUNKNOWNdrugstructuredosagenumb1drugstructuredosageunit003drugseparatedosagenumb3drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext1 MG, TIDdrugdosageformTABLETdrugadministrationroute048drugindicationPANIC ATTACKdrugenddateformat102drugenddate06/03/2014actiondrug4

2)

drugcharacterization1medicinalproductCLONAZEPAM (AELLC)drugbatchnumbUNKNOWNdrugstructuredosagenumb1drugstructuredosageunit003drugseparatedosagenumb3drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext1 MG, TIDdrugdosageformTABLETdrugadministrationroute048drugstartdateformat102drugstartdate18/03/2014actiondrug4

3)

drugcharacterization2medicinalproductSEROQUELdrugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextUNK, DAILYdrugadministrationroute048drugindicationBIPOLAR DISORDERdrugrecurreadministration3

openFDA Info on Medication

Application NumberNDA022047, NDA020639Brand NameSEROQUEL XR, SEROQUELGeneric NameQUETIAPINEManufacturersAstraZeneca Pharmaceuticals LPproduct_ndc 0310-0280, 0310-0282, 0310-0283, 0310-0284, 0310-0281, 0310-0271, 0310-0275, 031 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsQUETIAPINE FUMARATERXCUI 721791, 721793, 721794, 721795, 721796, 721797, 853201, 853202, 895670, 895671, ... spl_id1a826d85-aac4-42e4-a3e2-a18df915dc33, bca31730-a1ed-4b8f-93d8-2f64143a91faspl_set_id473a3ac4-67f4-4782-baa9-7f9bdd8761f4, 0584dda8-bc3c-48fe-1a90-79608f78e8a0Package NDC 0310-0282-39, 0310-0282-94, 0310-0282-60, 0310-0283-39, 0310-0283-55, 0310-0283- ... UNII2S3PL1B6UJ

4)

drugcharacterization2medicinalproductZOLOFTdrugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextUNK, DAILYdrugadministrationroute048drugindicationDEPRESSIONdrugrecurreadministration3

openFDA Info on Medication

Application NumberNDA020990, NDA019839Brand NameZOLOFTGeneric NameSERTRALINE HYDROCHLORIDEManufacturersRoerigproduct_ndc0049-0050, 0049-4960, 0049-4900, 0049-4910Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI208149, 208161, 212233, 312938, 312940, 312941, 861064, 861066spl_id665a145d-44fb-4fef-a3c1-2aac26e0715cspl_set_idfe9e8b7d-61ea-409d-84aa-3ebd79a046b5Package NDC 0049-4960-30, 0049-4960-50, 0049-4900-30, 0049-4900-66, 0049-4900-73, 0049-4900- ... UNIIUTI8907Y6X

Report Duplicate

duplicatesourceACTAVISduplicatenumbUS-ACTAVIS-2014-06267

Receiver

receivertype6receiverorganizationFDA

Sender

sendertype2senderorganizationFDA-Public Use

Adverse Event Report

Report

Primary Source

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

Drug

1)

2)

3)

openFDA Info on Medication

4)

openFDA Info on Medication

Report Duplicate

Receiver

Sender

Media

Newsletter

Follow us

Connect with us